St. Paul's Hospital Millennium Medical College, Ethiopia.
J Reprod Immunol. 2020 Nov;142:103180. doi: 10.1016/j.jri.2020.103180. Epub 2020 Jul 18.
Despite anticipated increased risk of COVID-19 and increased expression of the SARS CoV-2 receptor (ACE2), the relatively low mortality of pregnant women with COVID-19 has been an area of wonder. The immunological changes predominantly inclining to anti-inflammatory state, which is augmented by placental hormones' immune modulating action, looks against with COVID-19 inflammatory reaction leading to cytokine storm and multiple organ failure. Unlike many other viral infections, the bilateral immune activation of COVID-19 may preferentially make pregnant women at low risk. Taking the physiological advantage of pregnant women, potential clinical trials are proposed. Quite a large number of epidemiological and obstetrics related studies have addressed the cases of women with COVID-19. However, to the best of the author's knowledge, little is done to explore the physiological internal milieu of pregnant women in relation to COVID-19. This review provides an insight into how the hormonal and immunological changes in pregnancy potentially reduce SARS-CoV-2-mediated inflammatory response.
尽管预计 COVID-19 的风险增加,并且 SARS CoV-2 受体(ACE2)的表达增加,但 COVID-19 孕妇的死亡率相对较低一直是一个令人惊讶的领域。免疫变化主要倾向于抗炎状态,这是由胎盘激素的免疫调节作用增强的,与 COVID-19 导致细胞因子风暴和多器官衰竭的炎症反应相反。与许多其他病毒感染不同,COVID-19 的双侧免疫激活可能使孕妇处于低风险状态。利用孕妇的生理优势,提出了潜在的临床试验。相当多的流行病学和产科相关研究已经涉及到 COVID-19 女性的病例。然而,据作者所知,很少有人探讨 COVID-19 与孕妇生理内环境的关系。这篇综述深入探讨了妊娠期间激素和免疫变化如何潜在地降低 SARS-CoV-2 介导的炎症反应。